Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jessica L. Krakow"'
Autor:
Ying Zhu, Danielle E Dettling, Eilene Kwok, Lucy Quach, Aakash Datt, Jeremiah D Degenhardt, Anand Panchal, Pui Seto, Jessica L Krakow, Russell Wall, Brian J Hillier, Maia Vinogradova, Robert B DuBridge, Chad May
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/c0d4502e962a41b08a1e2dfef4485839
Autor:
Danielle E Dettling, Eilene Kwok, Lucy Quach, Aakash Datt, Jeremiah D Degenhardt, Anand Panchal, Pui Seto, Jessica L Krakow, Russell Wall, Brian J Hillier, Ying Zhu, Maia Vinogradova, Robert B DuBridge, Chad May
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e004336
BackgroundDespite clinical success with T cell engagers (TCEs) targeting hematological malignancies, achieving a safe and efficacious dose in patients with solid tumors remains challenging. Due to potency, low levels of target antigen expression on n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6442899ddb12569f97e7248a2000f18
https://doi.org/10.1136/jitc-2021-004336
https://doi.org/10.1136/jitc-2021-004336
Autor:
Maia Vinogradova, Danielle E. Dettling, Russell Wall, Jessica L. Krakow, Aakash Datt, Elizabeth Pongo, Tseng-Hui T Chen, Andisheh Bagheri, Brian J. Hillier, Patricia Culp, Ying Zhu, Chad May, Robert B. Dubridge, Jeremiah D. Degenhardt, Pui Seto, Anand Panchal
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Conditionally active COBRA™ (COnditional Bispecific Redirected Activation) T cell engagers are engineered to overcome the limitations of inherently active first-generation T cell engagers, which are unable to discern between tumor and healthy tissu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab2fd557a45866fee279d7f92d7371bd
https://doi.org/10.1080/19420862.2020.1792130
https://doi.org/10.1080/19420862.2020.1792130
Autor:
Ying Zhu, Lucy Quach, Robert B. Dubridge, Maia Vinogradova, Jeremiah D. Degenhardt, Anand Panchal, Chad May, Danielle E. Dettling, Pui Seto, Aakash Datt, Russell Wall, Jessica L. Krakow, Brian J. Hillier, Eilene Kwok
Publikováno v:
Cancer Research. 79:557-557
Despite clinical success with bispecific antibodies (bsAbs) targeting hematological malignancies (e.g. blinatumomab, a CD19xCD3 bsAb), efficacy in solid tumor indications remains a significant challenge. Because T cell redirecting bsAbs are so potent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1885b3fdcd6cc3f0cc50b52c7c2527cf
https://doi.org/10.1158/1538-7445.am2019-557
https://doi.org/10.1158/1538-7445.am2019-557